A new drug for Neovascular (Wet) Age-Related Macular Degeneration (nAMD) that offers treatment effect with once every 4-month administration has landed in Korea. The new option is expected to greatly improve the convenience of administration in domestic patients whose number has been increasing with Korea’s aging population.

Roche Korea held a press conference on the 7th to celebrate the approval of Vabysmo (faricimab) at its headquarters in Seocho-gu, Seoul.

Vabysmo is the first bispecific antibody that targets both the VEGF that is commonly targeted by existing ocular disease treatments as well as angiopoietin-2 (Ang-2) that are considered to be the cause of retinal disease to block both